NSPH
Nanosphere, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, May 23, 12:48 PM
    | Mon, May 23, 12:48 PM
  • Mon, May 23, 9:16 AM
    | Mon, May 23, 9:16 AM
  • Fri, May 20, 7:32 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $12 (140% upside) price target by Chardan Capital.
    • Amicus Therapeutics (NASDAQ:FOLD) initiated with Buy rating and $10 (45% upside) price target by Bank of America.
    • Quorum Health (NYSE:QHC) initiated with Equal Weight rating and $12 (2% upside) price target by Morgan Stanley.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $56 (30% upside) price target by Credit Suisse.
    • Prothena (NASDAQ:PRTA) initiated with Overweight rating and $60 (47% upside) price target by Barclays.
    • Mazor Robotics (NASDAQ:MZOR) upgraded to Outperform from Market Perform by Wells Fargo. Price target raised to $15-17 (14% upside from midpoint) from $10-13.
    • Eli Lilly (NYSE:LLY) upgraded to Strong Buy with a price target of $88.67 (19% upside) by the Vetr Community.
    • Haemonetics (NYSE:HAE) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $29 (5% upside) from $25.
    • Nanosphere (NASDAQ:NSPH) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $1.35 (2% upside) from $2.00.
    • Anacor Pharmaceuticals (NASDAQ:ANAC) downgraded to Neutral from Buy by Mizuho Securities. Price target set at $99.25 (0% upside).
    • Globus Medical (NYSE:GMED) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $21 (10% downside risk) from $26.
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $0.75 (27% upside).
    | Fri, May 20, 7:32 AM | 10 Comments
  • Mon, May 16, 7:25 AM
    • Nanosphere (NSPH) Q1 results: Revenues: $6.6M (+43.5%); R&D Expense: $3.7M (+2.8%); SG&A: $4.9M (-5.8%); Operating Loss: ($5.6M) (+22.2%); Net Loss: ($6.6M) (+12.0%); Loss Per Share: ($0.55) (+57.4%); Quick Assets: $13.4M (-11.3%).
    • No guidance given.
    | Mon, May 16, 7:25 AM
  • Mon, May 16, 6:50 AM
    • Luminex (NASDAQ:LMNX) agrees to acquire Nanosphere (NASDAQ:NSPH) for $58M in cash or $1.35 per share, a 73% premium over Friday's close of $0.78. The transaction will be financed with cash on hand. The deal, expected to close in Q2, should be accretive to non-GAAP earnings by the end of 2017.
    • Nanosphere generated ~$21M in revenue in 2015 and $6.6M in Q1 2016. It is expected to add $13M to $16M to Luminex's top line this year. The molecular diagnostics company's lead product is the Verigene system, which detects pathogens like Gram-positive and Gram-negative bacteria and Clostridium difficile.
    • Luminex will host a conference call this morning at 8:30 am ET to discuss the transaction.
    • Update: On May 23, Luminex ups its offer to $1.70 per share or $77M in response to a competitive bid at $1.50 per share.
    | Mon, May 16, 6:50 AM | 1 Comment
  • Mon, May 16, 6:04 AM
    • Nanosphere (NASDAQ:NSPH): Q1 EPS of -$0.55 beats by $0.04.
    • Revenue of $6.59M (+42.6% Y/Y) beats by $0.09M.
    | Mon, May 16, 6:04 AM
  • Wed, Mar. 9, 10:35 AM
    • Ultragenyx (RARE -1.5%) initiated with Outperform rating and $85 (44% upside) price target by Baird.
    • BioMarin Pharmaceutical (BMRN -1.6%) initiated with Outperform rating and $110 (33% upside) price target by Baird.
    • Nanosphere (NSPH +1.1%) initiated with Buy rating and $2 (117% upside) price target by Rodman & Renshaw.
    • BioSpecifics Technologies (BSTC -0.9%) initiated with Buy rating and $60 (68% upside) price target by Rodman & Renshaw.
    • Proteostasis Therapeutics (PTI +7.5%) initiated with Buy rating and $15 (67% upside) price target by H.C. Wainwright. Initiated with Outperform rating and $20 (122% upside) price target by RBC Capital. Initiated with Outperform rating and $13 (44% upside) price target by Baird.
    • AveXis (AVXS -0.8%) initiated with Outperform rating and $31 (44% upside) price target by BMO Capital. Initiated with Buy rating and $28 (30% upside) price target by Goldman Sachs.
    • Delcath Systems (DCTH +2.8%) initiated with Buy rating and $1 (233% upside) price target by WallachBeth.
    • Amicus Therapeutics (FOLD -1.8%) upgraded to Buy from Neutral by Janney Capital. Price target raised to $12 (61% upside) from $10.
    • Celldex Therapeutics (CLDX +1.4%) downgraded to Hold from Buy by Jefferies. Price target lowered to $4 (10% upside) from $31.
    • MEDNAX (MD -0.2%) downgraded to Neutral from Positive by Susquehanna. Price target lowered to $70 (8% upside) from $94.
    • Roka Bioscience (ROKA -8.8%) downgraded to Market Perform from Outperform. Price target lowered to $1 (22% upside).
    • Zimmer Biomet Holdings (ZBH +0.1%) downgraded to Hold from Buy by Argus Research.
    | Wed, Mar. 9, 10:35 AM | 5 Comments
  • Wed, Feb. 24, 4:05 PM
    • Nanosphere (NASDAQ:NSPH): Q4 EPS of -$1.28 misses by $0.23.
    • Revenue of $6.85M (+47.3% Y/Y) beats by $1.55M.
    | Wed, Feb. 24, 4:05 PM
  • Tue, Feb. 23, 5:35 PM
  • Wed, Jan. 6, 5:08 PM
    • Thinly traded nano cap Nanosphere (NASDAQ:NSPH) is up 38% after hours on average volume in response to its announcement of preliminary 2015 results. Top line revenue for Q4 and 2015 should be $6.8M (+48%) and $21.0M (+47%), respectively. It also reports 35 new customer placements in Q4 for its Verigene analyzer.
    • Final results and 2016 guidance will be announced next month.
    | Wed, Jan. 6, 5:08 PM
  • Dec. 18, 2015, 9:56 AM
    • Nanosphere (NSPH +32.6%) prices its $10M public offering of common stock at $0.47 per share, each coupled with a five-year warrant to purchase one share of common at $0.70.
    • Net proceeds will fund working capital and general corporate purposes.
    | Dec. 18, 2015, 9:56 AM
  • Dec. 17, 2015, 6:46 PM
    • Molecular diagnostics specialist Nanosphere (NASDAQ:NSPH) has priced a public offering with expected gross proceeds at $10M.
    • The pricing comes to $0.47/share of common stock; shares closed today down 10.2% to $0.485. Each share of common stock is coupled with a five-year warrant to buy another share of common stock with a $0.70 exercise price.
    • The offering is set to close on or about Tuesday. The company plans to use proceeds for working capital and general purposes.
    | Dec. 17, 2015, 6:46 PM
  • Dec. 10, 2015, 2:59 AM
    • New Ebola cases have surfaced in Liberia, the worst hit of all Ebola-affected nations, suggesting that the fight against the disease could take months, or even years, to fully eliminate.
    • Recent scientific studies and case reports indicate the Ebola virus can persist in survivors' bodily fluids months longer than previously thought.
    • Liberia has already been declared Ebola-free (42 days pass without a new episode of hemorrhagic fever) twice this year, only to see new cases appear.
    • Previously: Sierra Leone declared free of Ebola (Nov. 08 2015)
    • Ebola-related stocks: JNJ, GSK, HEB, BCRX, NLNK, NNVC, INO, OTCQB:GOVX, SRPT, CMRX, PLX, NSPH, LAKE, APT, VSR, SMED
    | Dec. 10, 2015, 2:59 AM | 15 Comments
  • Nov. 9, 2015, 4:06 PM
    • Nanosphere (NASDAQ:NSPH): Q3 EPS of -$1.31 misses by $0.16.
    • Revenue of $4.9M (+32.8% Y/Y) beats by $0.01M.
    | Nov. 9, 2015, 4:06 PM
  • Nov. 8, 2015, 5:35 PM
  • Sep. 9, 2015, 12:44 PM
    | Sep. 9, 2015, 12:44 PM